Norway· NO-ID_0CAA6186-8F36-4171-A0F9-447470D7D971
Omlyclo
A omalizumab product containing omalizumab, registered in Norway by Celltrion Healthcare Hungary Kft.. The same ATC class is registered in 16 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Omalizumab is registered in 16 of 19 countries.
Countries holding a registration under ATC R03DX05 (omalizumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 10 of them publish a price we can compare per daily dose
Omalizumab · ATC R03DX05
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of omalizumab costs, country by country.
Normalised to the WHO defined daily dose (16 mg), the median price runs from $0.26 in Czechia to $48.02 in Switzerland — a ×186 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Omalizumab · price per daily dose (16 mg)
USD · FX 28 Sept 2026
- CH Switzerland$48.02
- CZ Czechia$0.26
The record
At a glance
FEST (Norway)- Active substance
- Omalizumab
- Manufacturer
- Celltrion Healthcare Hungary Kft.
- Country
- Norway (NO)
- ATC code
- R03DX05
- ATC class
- Omalizumab
- Defined daily dose
- 16 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_0CAA6186-8F36-4171-A0F9-447470D7D971
- no_varenummer5074641NOK 2734.9
- gtin5996537021142
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
8 interactions on record for omalizumab.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Omalizumab · interactions on record
8 records
- 1 moderate
- 7 minor
Most severe, free to view
- Omacetaxine mepesuccinateL01XX40moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Omalizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOMLYCLOCelltrion Healthcare Hungary Kft., Budapest
- United KingdomOmlyclo 150mg/1ml solution for injection pre-filled pensCelltrion Healthcare UK Ltd
- SwedenOmlyclo 150 mg Injektionsvätska, lösning i förfylld injektionspennaCelltrion Healthcare Hungary Kft
- PolandOmlycloCelltrion Healthcare Hungary Kft.
- BelgiumOmlyclo 150 mgCelltrion Healthcare Hungary
- IcelandOmlycloCelltrion Healthcare Hungary Kft.
- SpainOMLYCLO 150 MG SOLUCION INYECTABLE EN JERINGA PRECARGADACelltrion Healthcare Hungary Kft.
- FinlandOmlycloOrifarm Oy
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Omlyclo, Xolair
- Liechtenstein · Omlyclo, Xolair
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8ea5c025-e755-49ee-a92d-e727eb09c0a1 GET /v1/drugs/8ea5c025-e755-49ee-a92d-e727eb09c0a1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt sprøyte",
"source": "fest",
"status": "A",
"atc_name": "Omalizumab",
"merkevare_id": "ID_0CAA6186-8F36-4171-A0F9-447470D7D971",
"name_form_strength": "Omlyclo inj, oppl 150 mg",
"prescription_group": "C"
}See everything about omalizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.